Cargando…

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy

Identifying patients at risk of poor response to neoadjuvant chemoradiotherapy (nCRT) is an emerging clinical need in locally advanced rectal cancer (LARC). SMAD3 is a key player in the chemoradio-resistance phenotype and its expression is both constitutive and locally induced. The aim was to invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Mattia, Elena, Canzonieri, Vincenzo, Polesel, Jerry, Mezzalira, Silvia, Dalle Fratte, Chiara, Dreussi, Eva, Roncato, Rossana, Bignucolo, Alessia, Innocente, Roberto, Belluco, Claudio, Pucciarelli, Salvatore, De Paoli, Antonino, Palazzari, Elisa, Toffoli, Giuseppe, Cecchin, Erika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740633/ https://www.ncbi.nlm.nih.gov/pubmed/35002714 http://dx.doi.org/10.3389/fphar.2021.778781

Ejemplares similares

A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
por: Dalle Fratte, Chiara, et al.
Publicado: (2022)

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients
por: Dreussi, Eva, et al.
Publicado: (2016)

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Dreussi, Eva, et al.
Publicado: (2016)

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2020)

Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis
por: De Mattia, Elena, et al.
Publicado: (2023)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population
por: De Mattia, Elena, et al.
Publicado: (2017)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm
por: De Mattia, Elena, et al.
Publicado: (2021)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy Outcomes
por: Mezzalira, Silvia, et al.
Publicado: (2019)

Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies
por: Belluco, Claudio, et al.
Publicado: (2011)

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure
por: Gagno, Sara, et al.
Publicado: (2023)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
por: De Mattia, Elena, et al.
Publicado: (2023)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy
por: Repetto, Ombretta, et al.
Publicado: (2017)

Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: D’Alimonte, Lucrezia, et al.
Publicado: (2020)

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy
por: Roncato, Rossana, et al.
Publicado: (2019)

Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer
por: Zanusso, Chiara, et al.
Publicado: (2017)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
por: Garziera, Marica, et al.
Publicado: (2019)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response
por: Belluco, Claudio, et al.
Publicado: (2016)

18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy
por: Capelli, Giulia, et al.
Publicado: (2022)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib
por: Dalle Fratte, Chiara, et al.
Publicado: (2020)

Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer
por: Innocente, Roberto, et al.
Publicado: (2021)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023)

The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients
por: Rampazzo, Enrica, et al.
Publicado: (2018)

Correction: The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients
por: Rampazzo, Enrica, et al.
Publicado: (2018)

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer
por: De Re, Valli, et al.
Publicado: (2009)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
por: Scarabel, Lucia, et al.
Publicado: (2022)

Genetic Variants of the TERT Gene, Telomere Length, and Circulating TERT as Prognostic Markers in Rectal Cancer Patients
por: Rampazzo, Enrica, et al.
Publicado: (2020)

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
por: Buonadonna, Angela, et al.
Publicado: (2023)

rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy
por: Zanusso, Chiara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_moluvsbjqnslmk3lq3ht9q19kf